ArticleJournal of spine surgery (Hong Kong)2026
Impact of perioperative GLP-1 agonist use on pseudarthrosis rates following single-level anterior cervical discectomy and fusion: a propensity-matched cohort study.
Article in Journal of spine surgery (Hong Kong), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.North American Spine Society journal · 2026Review
- GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anterior cervical discectomy and fusion (ACDF) is a widely performed surgical procedure for treating cervical spine pathologies, with pseudarthrosis remaining a significant postoperative challenge. While glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated beneficial effects on vascular health and bone metabolism, their impact on cervical fusion outcomes remains unexplored. This study investigates the relationship between perioperative GLP-1 agonist use and pseudarthrosis rates following single-level ACDF procedures. Methods: We conducted a retrospective propensity-matched cohort study using the TriNetX database. retrospective analysis using the TriNetX Research Network database, examining records from October 2010 to October 2022. The study population included patients who underwent single-level ACDF procedures. One-to-one propensity score matching (PSM) was performed to account for demographic factors, body mass index (BMI), hemoglobin A1c (HbA1c), and relevant comorbidities. Pseudarthrosis rates were evaluated at 6 months, 1 year, and 2 years postoperatively. Results: Of 28,133 patients who underwent ACDF, 555 were prescribed GLP-1 agonists within 6 months of surgery. After PSM, 546 patients were included in each cohort. The GLP-1 agonist cohort demonstrated significantly lower odds of developing pseudarthrosis at 6 months [odds ratio (OR): 0.60, 95% confidence interval (CI): 0.42-0.87], 1 year (OR: 0.65, 95% CI: 0.46-0.94), and 2 years (OR: 0.62, 95% CI: 0.44-0.86) postoperatively compared to the non-GLP-1 agonist cohort. Conclusions: GLP-1 agonist use was associated with significantly reduced pseudarthrosis rates following ACDF procedures across all measured time points. These findings suggest potential benefits of GLP-1 agonists in cervical fusion outcomes, independent of their metabolic effects. Further prospective studies are warranted to validate these results and elucidate the underlying biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.